Candel Therapeutics, Inc. (CADL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$12.17-3.41%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Move from losses to positive earnings: EPS -0.52 vs target 0.22.
Candel is developing new cancer treatments with promising trial data. Prostate cancer data raised price targets. The company aims to start phase 3 trials for lung cancer. Management confidence improved by 8 points recently.
The company is still losing money and missed earnings several times. Phase 3 trial concerns hurt the stock. There is no clear revenue growth yet.
The market values Candel near $5.15 per share, reflecting hopes for a turnaround. Our view aligns with this fair value but sees risk in trial progress.
Breaks if: Phase 3 trial initiation delayed or halted in 2026
Breaks if: EPS remains negative or below $0 in FY27
BLA submission missed or rejected in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces challenges, but it is preparing for potential regulatory and commercial milestones in the healthcare sector.
The market appears to have priced in a level of fragility due to the company's expensive valuation, which does not fully reflect its weak performance and elevated risks. There is a low tier of fragility, suggesting that while the stock is costly, it may not be overly sensitive to immediate changes.
Fundamentals are likely to remain weak in the near term, given the company's recent earnings miss and the high probability of missing future estimates. However, management is making progress on key initiatives, which could support a more stable trajectory over the multi-year horizon.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. The company reported an EPS of -0.52, missing the consensus estimate of -0.22. This performance sits well below its industry cohort, raising concerns about future growth.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The thesis hinges on several factors, including the company's ability to meet its regulatory submission timeline for aglatimagene and the overall performance of the healthcare sector. Additionally, any cuts to guidance or continued weakness in the jobs report could negatively impact sentiment.
In the next 1 to 3 years, CADL's performance will depend on its execution of key priorities and the broader market conditions in healthcare. Not investment advice.